This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in the Cards for Sarepta (SRPT) This Earnings Season?
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) Exondys 51 likely to drive second-quarter sales.
Exelixis (EXEL) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Exelixis' (EXEL) second-quarter 2019 results are expected to benefit from increase in Cabometyx sales. Investors will focus on other pipeline updates as well.
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) cardiovascular drug, Vascepa is expected to drive sales in the second quarter.
Will Strong HIV Sales Drive Gilead's (GILD) Q2 Earnings?
by Zacks Equity Research
Investors are expected to focus on the HIV franchise's performance and other pipeline updates, when Gilead (GILD) reports second-quarter 2019 results.
Vertex (VRTX) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex's (VRTX) second-quarter earnings call, investor focus will be on the adoption of its newest CF drug Symdeko and the update on its NDA filing for the VX-445 triple combination regimen.
Will Strong Jakafi Sales Drive Incyte (INCY) Q2 Earnings?
by Zacks Equity Research
Investors will primarily focus on Jakafi sales and pipeline updates, when Incyte (INCY) reports second-quarter 2019 results.
5 Drug/Biotech Stocks Set to Beat Earnings Estimates in Q2
by Zacks Equity Research
We take a look at the overall drug/biotech sector's performance and five stocks that are poised to beat on earnings in the second quarter of 2019.
Acorda (ACOR) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Acorda's (ACOR) second-quarter earnings call, investor focus will be on the sales uptick of its newly launched Parkinson's disease drug Inbrija.
What's in the Cards for AcelRx (ACRX) This Earnings Season?
by Zacks Equity Research
AcelRx (ACRX) will provide updates on the launch and sales of Dsuvia when it releases second-quarter 2019 results.
Eli Lilly (LLY) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead to an earnings beat for the company in Q2.
Is a Beat in Store for Repligen (RGEN) This Earnings Season?
by Zacks Equity Research
On Repligen's (RGEN) second-quarter earnings call, investor focus will be on its advancement with the proposed acquisition of C Technologies, Inc.
AMAG (AMAG) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
We expect AMAG (AMAG) to provide updates on its revenue-driving products, when it reports second-quarter earnings.
What's in Store for Anika Therapeutics' (ANIK) Q2 Earnings?
by Zacks Equity Research
On Anika Therapeutics' (ANIK) second-quarter earnings call, investor focus will be on its progress with the U.S. approval of its orthopedic product Cingal.
Alexion (ALXN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Soliris' solid performance is likely to reflect in Alexion's (ALXN) second-quarter 2019 results.
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?
by Zacks Equity Research
While sales of Biogen's (BIIB) MS franchise are expected to decline in the second quarter of 2019, Spinraza U.S. sales may improve.
Inovio (INO) Ends Some Early-Stage R&D Programs, Cuts Jobs
by Zacks Equity Research
Inovio (INO) stops the phase I/II study on INO-5401 for advanced bladder cancer and cuts its workforce by 28% and annual burn rate by 25%. Shares fall in after-hours trading.
4 Medical Stocks to Consider After Federal Judge Blocks Trump Proposal
by Christopher Vargas
In early May, President Donald Trump announced that he would be requiring Big Pharma to list the prices of their drugs in their TV advertisements.
FDA Accepts Sanofi's BLA for Myeloma Candidate to Review
by Zacks Equity Research
The FDA accepts for review Sanofi's (SNY) BLA for isatuximab as a potential treatment for relapsed/refractory multiple myeloma. The FDA will declare its decision by April 2020.
Glaxo's Dovato Wins EU Nod, RA Candidate Enters Phase III
by Zacks Equity Research
Glaxo (GSK) gets an EU approval for Dovato, its single-tablet two-drug HIV regimen. It commences phase III studies on its anti GM-CSF antibody, otilimab, for patients with rheumatoid arthritis.
Pfizer's Eucrisa Proves Safety in Kids with Atopic Dermatitis
by Zacks Equity Research
Pfizer's (PFE) Eucrisa ointment is found safe in a late-stage label expansion study for treating mild to moderate atopic dermatitis in minors aged 3 months to 2 years.
Regeneron/Sanofi's Libtayo Gets EU Approval for Skin Cancer
by Zacks Equity Research
Regeneron (REGN) wins approval for skin cancer drug, Libtayo, in the European Union.
Regeneron/Sanofi's Dupixent Gets Positive CHMP Recommendation
by Zacks Equity Research
Regeneron's (REGN) Dupixent gets favorable recommendation from CHMP for moderate-to-severe atopic dermatitis in adolescents aged 12-17 years.
Regeneron & Sanofi Get FDA Nod for Dupixent Label Expansion
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi obtain FDA approval for Dupixent for the treatment of chronic rhinosinusitis with nasal polyposis in adults.
Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More
by Zacks Equity Research
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza
by Zacks Equity Research
Ocular (OCUL) clinches the FDA approval for the label expansion of Dextenza to treat ocular inflammation following ophthalmic surgery.